Analysts Set Hims & Hers Health, Inc. (NYSE:HIMS) Target Price at $32.50

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have received an average recommendation of “Hold” from the sixteen analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and four have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $32.50.

Several equities analysts recently commented on HIMS shares. Wall Street Zen upgraded Hims & Hers Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Canaccord Genuity Group boosted their price target on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Barclays decreased their price objective on shares of Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating on the stock in a research report on Friday, August 21st. Citigroup reduced their target price on Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Finally, Needham & Company LLC increased their price target on shares of Hims & Hers Health from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $27.66 on Wednesday. The firm has a market cap of $6.45 billion, a price-to-earnings ratio of -43.90 and a beta of 2.42. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93. Hims & Hers Health has a 52 week low of $13.74 and a 52 week high of $65.30. The firm’s 50-day simple moving average is $31.67 and its two-hundred day simple moving average is $26.82.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The company had revenue of $753.21 million during the quarter, compared to analysts’ expectations of $698.90 million. During the same quarter in the previous year, the firm earned $0.17 earnings per share. The firm’s revenue was up 38.2% compared to the same quarter last year.

Insiders Place Their Bets

In other Hims & Hers Health news, COO Michael Chi sold 14,027 shares of the firm’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total transaction of $441,850.50. Following the completion of the transaction, the chief operating officer owned 432,124 shares of the company’s stock, valued at approximately $13,611,906. This trade represents a 3.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Soleil Boughton sold 25,111 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $27.55, for a total transaction of $691,808.05. Following the completion of the sale, the insider owned 313,964 shares in the company, valued at approximately $8,649,708.20. This trade represents a 7.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 190,227 shares of company stock worth $6,133,613. 11.76% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in HIMS. MassMutual Private Wealth & Trust FSB raised its holdings in Hims & Hers Health by 70.0% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after purchasing an additional 319 shares during the period. Sigma Planning Corp increased its position in Hims & Hers Health by 1.5% in the first quarter. Sigma Planning Corp now owns 26,007 shares of the company’s stock worth $540,000 after buying an additional 388 shares in the last quarter. Captrust Financial Advisors raised its stake in shares of Hims & Hers Health by 3.1% in the second quarter. Captrust Financial Advisors now owns 14,612 shares of the company’s stock worth $728,000 after buying an additional 443 shares during the period. Binnacle Investments Inc bought a new position in shares of Hims & Hers Health in the third quarter worth about $28,000. Finally, Northwestern Mutual Investment Management Company LLC lifted its position in shares of Hims & Hers Health by 1.1% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 46,607 shares of the company’s stock valued at $1,513,000 after buying an additional 521 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers continues to show strong top-line momentum: second-quarter revenue rose 38.2% year over year to $753.2 million and exceeded analyst expectations. The company also raised its 2026 revenue outlook, supported by weight-loss treatments, international expansion and artificial-intelligence initiatives. HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
• Neutral Sentiment: Analyst sentiment remains cautious. The consensus rating is “Hold,” with analysts recognizing the company’s growth opportunities while citing profitability pressure and uncertainty related to regulatory oversight.
• Negative Sentiment: Several investor-rights firms announced or promoted a securities-fraud class action against Hims & Hers and certain executives. The case covers investors who acquired securities between August 4, 2025, and July 29, 2026; investors must move for lead-plaintiff status by November 2, 2026. The repeated announcements increase concerns about potential legal expenses, penalties, management distraction and reputational damage. Rosen Law Firm HIMS Class Action Announcement
• Negative Sentiment: The litigation is tied to allegations stemming from an FTC complaint, including potentially deceptive privacy and billing practices. Claims that consumer health information may have been shared with advertising platforms and that customers may have been charged soon after submitting prescription-intake forms create risks of enforcement actions and additional compliance costs. These claims remain allegations. Kessler Topaz HIMS Investor Alert
• Negative Sentiment: Insider Soleil Boughton sold 3,458 shares for approximately $98,000 under a pre-arranged Rule 10b5-1 trading plan. The transaction reduced the insider’s holdings by about 1.1%, making it a relatively small and scheduled sale, but it adds a modest negative signal amid the broader legal uncertainty. Hims & Hers Insider Sale

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.